Cetrorelix
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00050 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | hypertrichosis (disease) | KG + DL |
| 2 | Ambras type hypertrichosis universalis congenita | KG + DL |
| 3 | malformation syndrome with odontal and/or periodontal component | KG + DL |
| 4 | syndrome with a Dandy-Walker malformation as major feature | KG + DL |
| 5 | isolated genetic hair shaft abnormality | KG + DL |
| 6 | persistent fetal circulation syndrome | KG + DL |
| 7 | familial isolated trichomegaly | KG + DL |
| 8 | familial male-limited precocious puberty | KG + DL |
| 9 | aromatase excess syndrome | KG + DL |
| 10 | centra precocious puberty 1 | KG + DL |
| 11 | pelvic organ prolapse | KG + DL |
| 12 | female genital tuberculosis | KG + DL |
| 13 | physiological sexual disorder | KG + DL |
| 14 | genetic alopecia | KG + DL |
| 15 | X-linked congenital generalized hypertrichosis | KG + DL |
| 16 | idiopathic central precocious puberty | KG + DL |
| 17 | diffuse cutaneous mastocytosis | KG + DL |
| 18 | dysplasia of cervix | KG + DL |
| 19 | precocious puberty, central, 2 | KG + DL |
| 20 | amenorrhea (disease) | KG + DL |
| 21 | precocious puberty | KG + DL |
| 22 | allergic urticaria | KG + DL |
| 23 | isolated congenital growth hormone deficiency | KG + DL |
| 24 | ACTH-independent macronodular adrenal hyperplasia | KG + DL |
| 25 | pulmonary arteriovenous malformation (disease) | KG + DL |
| 26 | Cushing syndrome due to macronodular adrenal hyperplasia | KG + DL |
| 27 | pulmonary arterial hypertension | KG + DL |
| 28 | gonadal disease | KG + DL |
| 29 | monostotic fibrous dysplasia (disease) | KG + DL |
| 30 | pulmonary arterial hypertension associated with congenital heart disease | KG + DL |
| 31 | habitual spontaneous abortion | KG + DL |
| 32 | pulmonary arterial hypertension associated with schistosomiasis | KG + DL |
| 33 | pulmonary arterial hypertension associated with HIV infection | KG + DL |
| 34 | pulmonary arterial hypertension associated with chronic hemolytic anemia | KG + DL |
| 35 | pulmonary arterial hypertension associated with connective tissue disease | KG + DL |
| 36 | polyostotic fibrous dysplasia | KG + DL |
| 37 | syndrome with limb duplication, polydactyly, syndactyly, and/or hyperphalangy | KG + DL |
| 38 | non-syndromic brachydactyly | KG + DL |
| 39 | adrenocortical insufficiency | KG + DL |
| 40 | candidiasis | KG + DL |
| 41 | IgE responsiveness, atopic | KG + DL |
| 42 | pituitary dwarfism | KG + DL |
| 43 | familial adrenal hypoplasia with absent pituitary luteinizing hormone | KG + DL |
| 44 | hypotrichosis simplex of the scalp | KG + DL |
| 45 | sex differentiation disease | KG + DL |
| 46 | recalcitrant atopic dermatitis | KG + DL |
| 47 | PAGOD syndrome | KG + DL |
| 48 | diffuse alopecia areata | KG + DL |
| 49 | cold urticaria | KG + DL |
| 50 | 46,XY disorder of sex development | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.